Get startedLog in
    Picture of Isofol Medical AB (publ) logo

    ISOFOL — Isofol Medical AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Isofol Secures License Rights For Arfolitixorin In Autism

    Picture of Isofol Medical AB (publ) logoIsofol Medical AB (publ)
    18/03/2026 12:54
    March 18 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST:

ISOFOL SECURES LICENSE RIGHTS FOR ARFOLITIXORIN IN AUTISM

EXPANDED ITS GLOBAL EXCLUSIVE LICENSE AGREEMENT FOR ARFOLITIXORIN TO ALSO INCLUDE DEVELOPMENT AND COMMERCIALIZATION WITHIN AUTISM SPECTRUM DISORDER

IS DEVELOPING ARFOLITIXORIN - A NEXT-GENERATION FOLATE-BASED DRUG CANDIDATE

DRUG CANDIDATE HAS POTENTIAL TO FILL A KNOWN TREATMENT GAP IN CANCER CARE.

ARFOLITIXORIN IS NOW BEING TESTED IN A PHASE IB/II CLINICAL STUDY

Source text: ID:nMFN3KlYfg

Further company coverage: ISOFOL.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Isofol Medical AB (publ)

    See all news